Core Viewpoint - Qianhong Pharmaceutical reached a settlement with Jianyuan Trust regarding a payment dispute from a trust plan purchased in 2018, resulting in a one-time payment of 56.9943 million yuan, which will contribute approximately 48.45 million yuan to the company's 2025 profit [1][4]. Group 1: Qianhong Pharmaceutical - Qianhong Pharmaceutical invested 170 million yuan in the "Anxin Chuangyin 51 Hao" trust plan, which was originally due on December 29, 2019 [4]. - After a prolonged legal battle lasting five years, the company agreed to withdraw its lawsuit in exchange for half of the remaining principal and earnings, amounting to 56.9943 million yuan [4]. - The expected profit increase of approximately 48.45 million yuan will be recorded in the 2025 profit statement [4]. Group 2: Jianyuan Trust - Jianyuan Trust reported a total revenue of 150 million yuan for the first half of 2025, marking an 84.89% year-on-year increase, and a net profit of 40 million yuan, up 13.36% [4][5]. - The company added 117 new trust projects in the first half of 2025, corresponding to a new trust scale of 1,080.01 billion yuan, reflecting a 785% year-on-year growth [5]. - As of June 30, 2025, Jianyuan Trust's managed trust assets reached 3,378.91 billion yuan, a 33.44% increase from the beginning of the year [5]. Group 3: Financial Performance and Business Development - In 2024, Jianyuan Trust achieved total revenue of 310 million yuan, with a net profit of 53 million yuan, representing a 25.15% year-on-year growth [7]. - The company’s solid business became a significant pillar, with interest income from proprietary business increasing by 12% to 32.5149 million yuan [7]. - Jianyuan Trust's trust asset management scale reached 2,532 billion yuan by the end of 2024, with a substantial growth of 78% from the beginning of the year [7].